Education
About Us
Working with TipRanks
Follow Us
Strata Critical Medical (SRTA)
NASDAQ:SRTA
SRTA Stock Chart & Stats
$4.17
--
Market closed
$4.17
--
Day’s Range― - ―
52-Week Range$2.35 - $6.02
Previous CloseN/A
VolumeN/A
Average Volume (3M)777.11K
Market Cap
$362.74M
Enterprise Value$335.08M
Total Cash (Recent Filing)$61.23M
Total Debt (Recent Filing)$3.31M
Price to Earnings (P/E)9.6
Beta1.99
Next Earnings
May 12, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding86,989,140
10 Day Avg. Volume741,117
30 Day Avg. Volume777,114
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.42
Price to Sales (P/S)2.01
P/FCF Ratio-6.78
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue1.70
Enterprise Value/Gross Profit8.15
Enterprise Value/Ebitda-18.14
Forecast
1Y Price Target
$9.63Price Target Upside130.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.11
Revenue Forecast (FY)$266.50M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetA near-zero leverage profile with roughly $61M of cash gives management a multi-quarter runway to execute M&A and absorb integration costs. This financial flexibility reduces refinancing risk, supports the asset-light model, and permits strategic investments without immediate reliance on equity issuance.
Strong Organic Logistics GrowthSustained ~35% organic logistics growth indicates durable end-market demand and improving customer adoption of the company's DCD/NRP capabilities. Persistent volume growth drives scale benefits, supports gross profit expansion, and underpins the company’s ability to convert revenue into sustainable higher adjusted EBITDA over time.
M&A Platform Supported By Undrawn ABLAn undrawn, upsizable asset-based revolver plus management focus on bolt-on M&A creates a repeatable acquisition engine. Executing on mid-single-digit multiple deals can accelerate adjusted EBITDA growth, complement organic expansion, and scale clinical capabilities without materially increasing owned assets.
Bears Say
Persistent Negative Operating Cash FlowConsistent operating cash outflows and negative free cash flow limit internal funding for growth and expose the company to refinancing or dilution risk if losses persist. One-offs worsened Q4 cash conversion, but the underlying cash burn trend remains a durable constraint on capital allocation flexibility.
Core Operating Profitability WeaknessDespite a net income swing in 2025, negative EBIT/EBITDA across multiple years show operating margins are not yet sustainable. Reliance on non-operating items and one-offs to reach GAAP profits weakens earnings quality, meaning profitability must improve at the operating level for durable returns.
Industry & Regulatory Timing RiskMarket expansion assumptions depend on donor trends and regulatory changes (CMS/OPTN). Slower-than-expected donor growth or delayed policy rollouts compress addressable market and can slow new customer activation and the projected tailwind for DCD/NRP services, affecting long-term revenue scaling.
Strata Critical Medical News
SRTA FAQ
What was Strata Critical Medical’s price range in the past 12 months?
Strata Critical Medical lowest stock price was $2.35 and its highest was $6.02 in the past 12 months.
What is Strata Critical Medical’s market cap?
Strata Critical Medical’s market cap is $362.74M.
When is Strata Critical Medical’s upcoming earnings report date?
Strata Critical Medical’s upcoming earnings report date is May 12, 2026 which is in 50 days.
How were Strata Critical Medical’s earnings last quarter?
Strata Critical Medical released its earnings results on Mar 03, 2026. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of $0.01 by -$0.07.
Is Strata Critical Medical overvalued?
According to Wall Street analysts Strata Critical Medical’s price is currently Undervalued.
Does Strata Critical Medical pay dividends?
Strata Critical Medical does not currently pay dividends.
What is Strata Critical Medical’s EPS estimate?
Strata Critical Medical’s EPS estimate is -0.04.
How many shares outstanding does Strata Critical Medical have?
Strata Critical Medical has 86,989,140 shares outstanding.
What happened to Strata Critical Medical’s price movement after its last earnings report?
Strata Critical Medical reported an EPS of -$0.06 in its last earnings report, missing expectations of $0.01. Following the earnings report the stock price went up 6.904%.
Which hedge fund is a major shareholder of Strata Critical Medical?
Currently, no hedge funds are holding shares in SRTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Strata Critical Medical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.63 (130.94% Upside)
$9.63 (130.94% Upside)
Blogger Sentiment
Bullish
SRTA Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 3.1%
Last 30 Days ▲ 3.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
38.53%
12-Months-Change
Fundamentals
Return on Equity
16.46%
Trailing 12-Months
Asset Growth
29.27%
Trailing 12-Months
Company Description
Strata Critical Medical
Strata Critical Medical, Inc. provides time critical logistics solutions and specialized medical services to healthcare providers across the United States. The company operates as both an air and ground transporter of human organs for transplant. The company was formerly known as Blade Air Mobility, Inc. and change its name to Strata Critical Medical, Inc. in August 2025. The company was founded in 2014 and is headquartered in New York, New York.
SRTA Company Deck
SRTA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational momentum and financial improvement driven by robust organic logistics growth (35%+), a successful integration of the Keystone acquisition, significant gross profit and adjusted EBITDA improvement, and raised 2026 guidance. Key positives include no debt, a healthy cash balance (~$61M), an active M&A pipeline supported by an undrawn $30M facility, and regulatory trends that favor the company's DCD/NRP capabilities. Near-term weaknesses are largely execution and timing-related: a negative operating cash flow in Q4 driven by nonrecurring charges and working capital build from integration, a discrete aircraft corrosion/write-down, elevated SG&A from Keystone, and an anticipated sequential margin dip in Q1 due to mix and weather. Overall, the positives (sizable growth, margin improvement, guidance raises, strong balance sheet and strategic positioning) substantially outweigh the transient and integration-related lowlights.View all SRTA earnings summariesSRTA Stock 12 Month Forecast
Average Price Target
$9.63
▲(130.94% Upside)
Technical Analysis
―
AerSale Corporation
―
Sun Country Airlines Holdings
―
flyExclusive
―
Surf Air Mobility, Inc.
―
Ownership Overview
14.04% Insiders
10.74% Mutual Funds
35.71% Other Institutional Investors
22.60% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---